Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

E F M Wouters, D S Postma, B Fokkens, W C J Hop, J Prins, A F Kuipers, H R Pasma, C A J Hensing, E C Creutzberg, COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group, E F M Wouters, D S Postma, B Fokkens, W C J Hop, J Prins, A F Kuipers, H R Pasma, C A J Hensing, E C Creutzberg, COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group

Abstract

Background: Guidelines recommend inhaled corticosteroids (ICS) as maintenance treatment for patients with chronic obstructive pulmonary disease (COPD) with a post-bronchodilator forced expiratory volume in 1 second (FEV1) <50% predicted and frequent exacerbations, although they have only a small preventive effect on the accelerated decline in lung function. Combined treatment with ICS and long acting beta2 agonists (LABA) may provide benefit to the stability of COPD, but it is unknown if withdrawal of ICS will result in disease deterioration.

Methods: The effects of 1 year withdrawal of the ICS fluticasone propionate (FP) after a 3 month run-in treatment period with FP combined with the LABA salmeterol (S) (500 microg FP + 50 microg S twice daily; SFC) were investigated in patients with COPD in a randomised, double blind study. 497 patients were enrolled from 39 centres throughout the Netherlands; 373 were randomised and 293 completed the study.

Results: The drop out rate after randomisation was similar in the two groups. Withdrawal of FP resulted in a sustained decrease in FEV1: mean (SE) change from baseline -4.4 (0.9)% (S) v -0.1 (0.9)% (SFC); adjusted difference 4.1 (95% CI 1.6 to 6.6) percentage points (p<0.001). Corresponding figures for the FEV1/FVC ratio were -3.7 (0.8)% (S) v 0.0 (0.8)% (SFC) (p = 0.002). The annual moderate to severe exacerbation rate was 1.6 and 1.3 in the S and SFC groups, respectively (adjusted rate ratio 1.2; 95% CI 0.9 to 1.5; p = 0.15). The mean annual incidence rate of mild exacerbations was 1.3 (S) v 0.6 (SFC), p = 0.020. An immediate and sustained increase in dyspnoea score (scale 0-4; mean difference between groups 0.17 (0.04), p<0.001) and in the percentage of disturbed nights (6 (2) percentage points, p<0.001) occurred after withdrawal of fluticasone.

Conclusions: Withdrawal of FP in COPD patients using SFC resulted in acute and persistent deterioration in lung function and dyspnoea and in an increase in mild exacerbations and percentage of disturbed nights. This study clearly indicates a key role for ICS in the management of COPD as their discontinuation leads to disease deterioration, even under treatment with a LABA.

References

    1. BMJ. 2000 May 13;320(7245):1297-303
    1. Eur Respir J. 1997 Apr;10(4):815-21
    1. Am J Respir Crit Care Med. 2001 Aug 1;164(3):365-71
    1. Thorax. 2001 Nov;56(11):880-7
    1. Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1948-56
    1. Eur Respir J. 2002 Mar;19(3):398-404
    1. Eur Respir J. 2002 May;19(5):936-43
    1. Am J Respir Crit Care Med. 2002 Oct 15;166(8):1084-91
    1. Am J Respir Crit Care Med. 2002 Nov 15;166(10):1358-63
    1. Eur Respir J. 2003 Jan;21(1):68-73
    1. Eur Respir J. 2003 Jan;21(1):74-81
    1. Lancet. 2003 Feb 8;361(9356):449-56
    1. Eur Respir J. 1997 Apr;10(4):822-7
    1. Lancet. 1998 Mar 14;351(9105):773-80
    1. Chest. 1999 Apr;115(4):957-65
    1. Lancet. 1999 May 29;353(9167):1819-23
    1. N Engl J Med. 1999 Jun 24;340(25):1948-53
    1. Respir Med. 1999 Mar;93(3):161-6
    1. J Clin Invest. 2005 Feb;115(2):247-57
    1. Chest. 2003 Sep;124(3):834-43
    1. Thorax. 2003 Nov;58(11):937-41
    1. Eur Respir J. 2003 Dec;22(6):912-9
    1. Eur Respir J. 2003 Dec;22(6):931-6
    1. Thorax. 2004 Mar;59(3):181-2
    1. N Engl J Med. 2004 Jun 24;350(26):2689-97
    1. Am J Respir Crit Care Med. 1997 Apr;155(4):1283-9
    1. Respir Med. 2003 Mar;97 Suppl C:S3-14
    1. Am J Respir Crit Care Med. 2000 May;161(5):1608-13

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel